UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

Neurology, 2011-01, Vol.76 (3), p.219-226

2011

Volltextzugriff (PDF)

Use of a ≥ 5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy

European journal of paediatric neurology, 2017-06, Vol.21, p.e237-e237

2017

Volltextzugriff (PDF)

T.P.8

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.862-862

2014

Volltextzugriff (PDF)

G.P.115

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.829-830

2014

Volltextzugriff (PDF)

G.P.114

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.829-829

2014

Volltextzugriff (PDF)

Association study of exome variants in the NF-κB and TGFβ pathways identifies CD40 as a modifier of Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2016-10, Vol.26, p.S98-S98

2016

Volltextzugriff (PDF)

P.2.11 CINRG Duchenne Natural History Study: Relationship of longitudinal measures of ambulatory timed function tests and loss of clinical milestones

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.752-752

2013

Volltextzugriff (PDF)

P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.804-804

2013

Volltextzugriff (PDF)

166. Improvements in muscle function and accidental falling in ataluren-treated patients with nonsense mutation dystrophinopathy (Duchenne/Becker muscular dystrophy)

Clinical neurophysiology, 2012-06, Vol.123 (6), p.e64-e64

2012

Volltextzugriff (PDF)

G.P.167

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.855-856

2014

Volltextzugriff (PDF)

P.16.11 Upper extremity reachable workspace evaluation in FSHD using Kinect

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.825-826

2013

Volltextzugriff (PDF)

P.11.12 Pulmonary function characteristics of boys with Duchenne muscular dystrophy: Data from the CINRG longitudinal study project

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.802-802

2013

Volltextzugriff (PDF)

P.11.11 Pulmonary function characteristics of boys with Duchenne Muscular Dystrophy by age groups, ambulatory status and steroid use

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.801-802

2013

Volltextzugriff (PDF)

165. Development and validation of the 6-min walk test as a clinical endpoint in Duchenne and Becker muscular dystrophy

Clinical neurophysiology, 2012-06, Vol.123 (6), p.e64-e64

2012

Volltextzugriff (PDF)

P.2.9 The 6-min walk test and other endpoints in Duchenne MD: Multi center longitudinal natural history observations over 48 weeks

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.751-751

2013

Volltextzugriff (PDF)

P.2.4 Upper extremity reachable workspace evaluation in DMD using Kinect

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.749-750

2013

Volltextzugriff (PDF)

P.2.8 The 6-min walk test and clinical endpoints in Duchenne MD: Reliability, validity, and clinically-important differences

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.751-751

2013

Volltextzugriff (PDF)

P.2.6 Comparison of 6MWD and person-reported functional measures in boys with Duchenne muscular dystrophy aged 4–12 years

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.750-750

2013

Volltextzugriff (PDF)

P.7.16 One year outcome assessment of young boys with DMD using the Bayley-III Scales of Infant and Toddler Development

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.778-778

2013

Volltextzugriff (PDF)

Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids

Neuromuscular disorders : NMD, 2018-11, Vol.28 (11), p.897-909

2018

Volltextzugriff (PDF)

Household food insecurity and dietary diversity as correlates of maternal and child undernutrition in rural Cambodia

European journal of clinical nutrition, 2015-02, Vol.69 (2), p.242-246

2015

Volltextzugriff (PDF)

865 MITOCHONDRIAL DYSFUNCTION AND MUSCLE PH ABNORMALITY POST-EXERCISE: A TWO-HIT MECHANISM FOR FATIGUE PATHOGENESIS IN PRIMARY BILIARY CIRRHOSIS

Journal of hepatology, 2008, Vol.48, p.S325-S325

2008

Volltextzugriff (PDF)

Global optimization for the phase and chemical equilibrium problem: Application to the NRTL equation

Computers & chemical engineering, 1995, Vol.19 (11), p.1111-1139

1995

Volltextzugriff (PDF)

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

Neurology, 2011-08, Vol.77 (5), p.444-452

2011

Volltextzugriff (PDF)

T.P.1.02 The 6 min walk test (6MWT) as a clinical trial outcome measure in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Neuromuscular disorders : NMD, 2008-10, Vol.18 (9), p.739-739

2008

Volltextzugriff (PDF)

1 – 25 von 214

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(195)
Mit Volltextzugriff
(200)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(74)
Biological And Medical Sciences
(31)
Technology
(28)
Animals
(27)
Humans
(27)
Neurology
(23)
Fundamental And Applied Biological Sciences. Psychology
(22)
Female
(20)
Male
(20)
Engineering
(18)
Exact Sciences And Technology
(13)
Adult
(12)
Freshwater
(11)
Physical Sciences
(11)
Animal, Plant And Microbial Ecology
(10)
Medical Sciences
(10)
Toxicology
(10)
Applied Sciences
(9)
Engineering, Chemical
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

Use of a ≥ 5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy

T.P.8

G.P.115

G.P.114

Association study of exome variants in the NF-κB and TGFβ pathways identifies CD40 as a modifier of Duchenne muscular dystrophy

P.2.11 CINRG Duchenne Natural History Study: Relationship of longitudinal measures of ambulatory timed function tests and loss of clinical milestones

P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

166. Improvements in muscle function and accidental falling in ataluren-treated patients with nonsense mutation dystrophinopathy (Duchenne/Becker muscular dystrophy)

G.P.167

P.16.11 Upper extremity reachable workspace evaluation in FSHD using Kinect

P.11.12 Pulmonary function characteristics of boys with Duchenne muscular dystrophy: Data from the CINRG longitudinal study project

P.11.11 Pulmonary function characteristics of boys with Duchenne Muscular Dystrophy by age groups, ambulatory status and steroid use

165. Development and validation of the 6-min walk test as a clinical endpoint in Duchenne and Becker muscular dystrophy

P.2.9 The 6-min walk test and other endpoints in Duchenne MD: Multi center longitudinal natural history observations over 48 weeks

P.2.4 Upper extremity reachable workspace evaluation in DMD using Kinect

P.2.8 The 6-min walk test and clinical endpoints in Duchenne MD: Reliability, validity, and clinically-important differences

P.2.6 Comparison of 6MWD and person-reported functional measures in boys with Duchenne muscular dystrophy aged 4–12 years

P.7.16 One year outcome assessment of young boys with DMD using the Bayley-III Scales of Infant and Toddler Development

Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids

Household food insecurity and dietary diversity as correlates of maternal and child undernutrition in rural Cambodia

865 MITOCHONDRIAL DYSFUNCTION AND MUSCLE PH ABNORMALITY POST-EXERCISE: A TWO-HIT MECHANISM FOR FATIGUE PATHOGENESIS IN PRIMARY BILIARY CIRRHOSIS

Global optimization for the phase and chemical equilibrium problem: Application to the NRTL equation

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

T.P.1.02 The 6 min walk test (6MWT) as a clinical trial outcome measure in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Suchergebnisse filtern